Literature DB >> 15078953

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Joseph F Bower1, Xinzhen Yang, Joseph Sodroski, Ted M Ross.   

Abstract

DNA vaccines expressing the envelope (Env) of human immunodeficiency virus type 1 (HIV-1) have been relatively ineffective at generating high-titer, long-lasting immune responses. Oligomeric or trimeric (gp140) forms of Env that more closely mimic the native proteins on the virion are often more effective immunogens than monomeric (gp120) envelopes. In this study, several forms of Env constructed from the HIV-1 isolate YU-2 (HIV-1(YU-2)) were tested for their immunogenic potential: a trimeric form of uncleaved (-) Env stabilized with a synthetic trimer motif isolated from the fibritin (FT) protein of the T4 bacteriophage, sgp140(YU-2)(-/FT), was compared to sgp140(YU-2)(-) without a synthetic trimerization domain, as well as to monomeric gp120(YU-2). DNA plasmids were constructed to express Env alone or fused to various copies of murine C3d (mC3d). BALB/c mice were vaccinated (day 1 and week 4) with DNA expressing a codon-optimized envelope gene insert, alone or fused to mC3d. Mice were subsequently boosted (week 8) with the DNA or recombinant Env protein. All mice had high anti-Env antibody titers regardless of the use of mC3d. Sera from mice vaccinated with DNA expressing non-C3d-fused trimers elicited neutralizing antibodies against homologous HIV-1(YU-2) virus infection in vitro. In contrast, sera from mice inoculated with DNA expressing Env-C3d protein trimers elicited antibody that neutralized both homologous HIV-1(YU-2) and heterologous HIV-1(ADA), albeit at low titers. Therefore, DNA vaccines expressing trimeric envelopes coupled to mC3d, expressed in vivo from codon-optimized sequences, elicit low titers of neutralizing antibodies against primary isolates of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078953      PMCID: PMC387675          DOI: 10.1128/jvi.78.9.4710-4719.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer.

Authors:  C W Zhang; Y Chishti; R E Hussey; E L Reinherz
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

4.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  CD21 augments antigen presentation in immune individuals.

Authors:  S A Boackle; V M Holers; D R Karp
Journal:  Eur J Immunol       Date:  1997-01       Impact factor: 5.532

6.  Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.

Authors:  Xinzhen Yang; Juliette Lee; Erin M Mahony; Peter D Kwong; Richard Wyatt; Joseph Sodroski
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity.

Authors:  F Mustafa; J F Richmond; R Fernandez-Larsson; S Lu; R Fredriksson; E M Fenyö; M O'Connell; E Johnson; J Weng; J C Santoro; H L Robinson
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

8.  Codon usage limitation in the expression of HIV-1 envelope glycoprotein.

Authors:  J Haas; E C Park; B Seed
Journal:  Curr Biol       Date:  1996-03-01       Impact factor: 10.834

9.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.

Authors:  Norbert Schülke; Mika S Vesanen; Rogier W Sanders; Ping Zhu; Min Lu; Deborah J Anselma; Anthony R Villa; Paul W H I Parren; James M Binley; Kenneth H Roux; Paul J Maddon; John P Moore; William C Olson
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more
  39 in total

1.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

3.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 4.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

5.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

Review 6.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.

Authors:  Audray Harris; Mario J Borgnia; Dan Shi; Alberto Bartesaghi; Haifeng He; Robert Pejchal; Yun Kenneth Kang; Rafael Depetris; Andre J Marozsan; Rogier W Sanders; Per Johan Klasse; Jacqueline L S Milne; Ian A Wilson; William C Olson; John P Moore; Sriram Subramaniam
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

8.  Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Authors:  Joseph P Nkolola; Hanqin Peng; Ethan C Settembre; Michael Freeman; Lauren E Grandpre; Colleen Devoy; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Ritu Bradley; David C Montefiori; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

9.  Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.

Authors:  Zhenhua Zhang; Yongqing Li; Shufang Xu; Fuyong Chen; Li Zhang; Beiyu Jiang; Xiaoling Chen
Journal:  Virol J       Date:  2010-05-09       Impact factor: 4.099

10.  The rate of mutation of a single gene.

Authors:  Samuel J Balin; Marilia Cascalho
Journal:  Nucleic Acids Res       Date:  2009-12-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.